The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and develo** …

Abstract Purpose of Review Neuroendocrine prostate cancer (NEPC) is an aggressive
histologic subtype of prostate cancer that most commonly arises in later stages of prostate …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Notch signaling can have either an oncogenic or tumor-suppressive function in cancer
depending on the cancer type and cellular context. While Notch can be oncogenic in early …

During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20%
of advanced treatment-resistant prostate cancers, and this may manifest clinically as …

Neuroendocrine (NE) prostate cancer (NEPC) is a lethal subtype of castration-resistant
prostate cancer (PCa) arising either de novo or from transdifferentiated prostate …

Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay
of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens …